Cardiovascular related polypharmacy and its association with liver and kidney impairment amongst individuals on lipid-lowering therapy: a cross-sectional study using primary care data

Back

ESC Professional Premium Access

Cardiovascular related polypharmacy and its association with liver and kidney impairment amongst individuals on lipid-lowering therapy: a cross-sectional study using primary care data

Session: Lipid-lowering therapy: statins and beyond

Topic: Cardiovascular Pharmacotherapy

Speaker: Assistant Professor S. Talic (Melbourne, AU)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Assistant Professor Stella Talic

Monash University, Melbourne (Australia)

0 follower

6 more presentations in this session

Plasma statin concentrations do not correlate with statin-induced myalgia

Speaker: Doctor M. Ritvos (Helsinki, FI)

The high-dose statin treatment reduces neutrophil extracellular traps formation in patients with coronary artery disease

Speaker: Doctor K. Stepien (Krakow, PL)

Long-term administration of atorvastatin had no effect on the occurrence and progression of spontaneous hypertensive intracerebral hemorrhage in mice

Speaker: Doctor X. Bian (Beijing, CN)

Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry

Speaker: Doctor F. Marzano (Naples, IT)

Impact of allogenic Fecal Microbiota Transplantation (FMT) on lipid parameters in patients with metabolic syndrome (MetS): a meta-analysis

Speaker: Doctor L. Wang (Beijing, CN)

Access the full session

Lipid-lowering therapy: statins and beyond

Speakers: Assistant Professor S. Talic, Doctor M. Ritvos, Doctor K. Stepien, Doctor X. Bian, Doctor F. Marzano...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources